Insmed's Experimental Drug Brensocatib Achieves Major Trial Success

Shares more than double as Phase 3 results show significant reduction in lung disease symptoms, paving the way for FDA approval.

Brensocatib reduced pulmonary exacerbations by 20% in patients with non-cystic fibrosis bronchiectasis.
Insmed plans to apply for FDA approval in the fourth quarter of 2024.
The drug could be on the market by mid-2025, with launches in Europe and Japan to follow.
Analysts predict brensocatib could generate billions in annual sales if approved.
Insmed's market value surged to $7.3 billion following the trial results.